Search by Drug Name or NDC
NDC 00135-0095-41 GAVISCON 254; 237.5 mg/5mL; mg/5mL Details
GAVISCON 254; 237.5 mg/5mL; mg/5mL
GAVISCON is a ORAL LIQUID in the HUMAN OTC DRUG category. It is labeled and distributed by GlaxoSmithKline Consumer Healthcare Holdings (US) LLC. The primary component is ALUMINUM HYDROXIDE; MAGNESIUM CARBONATE.
Product Information
| NDC | 00135-0095 |
|---|---|
| Product ID | 0135-0095_0ab338be-56a6-284d-e063-6294a90a306f |
| Associated GPIs | 48990002151840 |
| GCN Sequence Number | 014148 |
| GCN Sequence Number Description | mag carb/aluminum hydrox/algin ORAL SUSP 237.5-254 ORAL |
| HIC3 | D4B |
| HIC3 Description | ANTACIDS |
| GCN | 63371 |
| HICL Sequence Number | 001172 |
| HICL Sequence Number Description | MAGNESIUM CARBONATE/ALUMINUM HYDROXIDE/ALGINIC ACID |
| Brand/Generic | Brand |
| Proprietary Name | GAVISCON |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | aluminum hydroxide and magnesium carbonate |
| Product Type | HUMAN OTC DRUG |
| Dosage Form | LIQUID |
| Route | ORAL |
| Active Ingredient Strength | 254; 237.5 |
| Active Ingredient Units | mg/5mL; mg/5mL |
| Substance Name | ALUMINUM HYDROXIDE; MAGNESIUM CARBONATE |
| Labeler Name | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | OTC MONOGRAPH DRUG |
| Application Number | M001 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00135-0095-41 (00135009541)
| NDC Package Code | 0135-0095-41 |
|---|---|
| Billing NDC | 00135009541 |
| Package | 355 mL in 1 BOTTLE (0135-0095-41) |
| Marketing Start Date | 2011-01-14 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |